A1M Pharma on getting lead compound into clinic

Mike Ward, global director of content for Informa Pharma Insights, talks to Martin Austin, director of business development at A1M Pharma, about the company's "protective" radiotherapeutic agent for acute kidney injury. A1M Pharma is developing a recombinant A1M molecule (rA1M) that can be used as a drug. The company will enter the clinic soon to carry out a proof-of-concept trial.